Oxyrane UK Limited

Universiteit Gent

Vib Vzw

Research Corporation Technologies, Inc.

Vrije Universiteit Brussel

Danisco US Inc.

University of Ghent

Flanders Interuniversity Inst. for Biotechnology Vzw

Wouter Vervecken

Michael D Ward

Kathleen Camilla Telesphore Alida Maria Piens

Steven Christian Jozef Geysens

Nico Luc Marc Callewaert

Karen Jacqueline Marcel De Pourcq

Mouna Guerfal

Gwenda Noëlla Pynaert

Kathleen Camilla Piens

Roland Henri Contreras

Nico L M Callewaert

Han Karel Remaut

Vladimir Kaigorodov

Petra Sophie Tiels

Albena Vergilieva Valevska

Jan Robert Ludo Stout

Gwenda Noella Pynaert

Steven Geysens

Nico Luc Callewaert

Nico L Callewaert

Karen Jacqueline Marcel De Pourq

Roland Contreras

Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.

Yeast strains producing mammalian-like complex n-glycans

The present invention provides new forms of human &#x3b1;-N-acetylgalactosaminidase (NAGAL) polypeptide or a functionally active variant or fragment thereof, nucleic acids encoding the same, and related products and uses, including use in methods of treating Fabry disease, Schindler disease or Kanzaki disease.

Human alpha-N-acetylgalactosaminidase polypeptide

This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell.

Methods and materials for treatment of Pompe's disease

Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide.

Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Methods for demannosylating phosphorylated N-glycans on a glycoprotein are described that use a mannosidase capable of hydrolyzing a terminal alpha-1,2 mannose linkage when the underlying mannose is phosphorylated.

De-mannosylation of phosphorylated N-glycans

Yeast strains producing mammalian-like complex N-glycans

Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.

Microorganisms genetically engineered to have modified N-glycosylation activity

The invention provides mannosidases capable of uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans, methods of using such mannosidases, glycoproteins produced using the methods, as well as methods of facilitating mammalian cellular uptake of glycoproteins.

Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins

Methods and materials for treatment of pompe's disease

Glycosylation of molecules

Growing community of inventors

Landskouter, Belgium

Wouter Vervecken